Posted by Michael Wonder on 01 Feb 2023
Mesoblast resubmits biologic license application to FDA for remestemcel-L in children with steroid-refractory acute graft versus host disease
31 January 2023 - New 4 year data from the Phase 3 trial shows durable long term survival outcomes.
Mesoblast announced today it has resubmitted to the US FDA its biologics license application for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.
